WaveMan
WaveMan · Company
CALC · Calcimedica, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CALC CalciMedica (CALC) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001534133
Quote by TradingView
Activist 13D
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
15
13F, latest reported quarter

What the filings say about CALC

Insiders, 180 days
+$199.2K net bought
1 buyer
Activist stakes (13D), 180 days
2 filings
Largest: 17.1% of the class

CalciMedica insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CalciMedica, Inc. insiders bought a net $199.2K of stock across 117 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Middleton Fred A
Director
BUY
2026-06-29 SECtraded 2026-06-25
248,972
$199.2K
+27.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 23.4% of the 1,063,272 shares held after it.
  • No other insider bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Middleton Fred A bought about $199.2K of CALC on Jun 25, 2026, the largest insider purchase at the company since 2024; 15 funds added in the latest 13F quarter.
Roberts Eric W
CHIEF BUSINESS OFFICER
BUY
2025-09-22 SECtraded 2025-09-18
2,500
$7.7K
-58.1%
Context
  • 50 earlier Form 4 trades (code P or S) here by this insider (50 buys), the last on Sep 15, 2025.
  • +13.1% median (+33.3% mean) 90-day return after 30 previous buys.
  • The trade is 3.0% of the 84,150 shares held after it.
  • 1 other insider bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF BUSINESS OFFICER Roberts Eric W bought about $7.7K of CALC on Sep 18, 2025; 1 other insider bought within 30 days and 15 funds added in the latest 13F quarter.
Roberts Eric W
CHIEF BUSINESS OFFICER
BUY
2025-09-17 SECtraded 2025-09-15
3,400
$9.1K
-59.2%
Context
  • 49 earlier Form 4 trades (code P or S) here by this insider (49 buys), the last on Sep 12, 2025.
  • +12.8% median (+30.5% mean) 90-day return after 30 previous buys.
  • The trade is 4.2% of the 81,650 shares held after it.
  • 1 other insider bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF BUSINESS OFFICER Roberts Eric W bought about $9.1K of CALC on Sep 15, 2025; 1 other insider bought within 30 days and 15 funds added in the latest 13F quarter.
Roberts Eric W
CHIEF BUSINESS OFFICER
BUY
2025-09-15 SECtraded 2025-09-12
5,000
$15.6K
-57.9%
Context
  • 48 earlier Form 4 trades (code P or S) here by this insider (48 buys), the last on Sep 9, 2025.
  • +12.0% median (+28.5% mean) 90-day return after 30 previous buys.
  • The trade is 6.4% of the 78,250 shares held after it.
  • 1 other insider bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF BUSINESS OFFICER Roberts Eric W bought about $15.6K of CALC on Sep 12, 2025; 1 other insider bought within 30 days and 15 funds added in the latest 13F quarter.
Roberts Eric W
CHIEF BUSINESS OFFICER
BUY
2025-09-11 SECtraded 2025-09-09
2,343
$7.4K
-58.7%
Context
  • 47 earlier Form 4 trades (code P or S) here by this insider (47 buys), the last on Aug 29, 2025.
  • +11.3% median (+27.1% mean) 90-day return after 30 previous buys.
  • The trade is 3.2% of the 73,250 shares held after it.
  • 1 other insider bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF BUSINESS OFFICER Roberts Eric W bought about $7.4K of CALC on Sep 9, 2025; 1 other insider bought within 30 days and 15 funds added in the latest 13F quarter.
117 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 112 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$199.2K over 180 days
+$199.2K of it by a 10%+ holder
more than 80% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
15 funds bought in last quarter
below 73% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.3% of the float short (float per yahoo 2026-10-26) · 1.5 days to cover · settled 2026-09-30
below 85% of Pharma & Biotech
The situation: each line is one rule over one dataset
Alafi Capital Company LLC disclosed a 5%+ stake (17.1%) in the last six months.
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CALC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-57.3%12M
-83%-16%+52%+120%2025-102025-122026-022026-042026-062026-082026-10 2026-06-25 · Middleton Fred A bought $199.2K2026-07-10 · Alafi Capital Company LLC filed a 5%+ stake (17.1%)2026-07-10 · Christopher D. Alafi filed a 5%+ stake (17.1%)2026-07-02 · Bering Partners II GP, L.L.C. filed a 5%+ stake (6.9%)2026-07-02 · Bering Partners II, L.P. filed a 5%+ stake (6.9%)2026-07-02 · Evgeny Zaytsev filed a 5%+ stake (6.9%)2026-07-02 · Philip M Sawyer filed a 5%+ stake (6.9%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CALC: institutional holders (13F)

13F holdings, latest reported quarter
Woodline Partners LP
2,489,729 sh
$2.6M
Stonepine Capital Management, LLC
2,751,029 sh
$1.8M
HEIGHTS CAPITAL MANAGEMENT, INC
1,556,081 sh
$1.6M
Squadron Capital Management LLC
1,244,864 sh
$1.3M
STEMPOINT CAPITAL LP
1,244,864 sh
$1.2M

Congress trades in CALC

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Alafi Capital Company LLC
Activist 13D · 2026-07-10
17.1%
Christopher D. Alafi
Activist 13D · 2026-07-10
17.1%
Bering Partners II GP, L.L.C.
Activist 13D · 2026-07-02
6.9%
Bering Partners II, L.P.
Activist 13D · 2026-07-02
6.9%
Evgeny Zaytsev
Activist 13D · 2026-07-02
6.9%

CALC planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

CALC mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$53.7K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$91.6K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$7.9K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$10.1K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$9.5K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
5
Phase 2
0 active
What changed recently
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
2026-09-01 · Active Not Recruiting → Terminated · The study was stopped due to imbalance in randomization stratification of severe patients.
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · A. Rachel Leheny
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$895.4K
$2.4M
$733.4K
+130%
n/a
2024
$1.7M
$1.5M
$1.3M
+24%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $199.2K bought by insiders over 180 days, 15 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CALC financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$19.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-365.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-110.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-124.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-42.7%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$23.1M-$24.2M-$38.1M-$14.2M
Net income-$29.6M-$13.7M-$34.4M-$7.8M
EPS (diluted)-1.97-1.22-7.66-111.16
Operating cash flow-$21.2M-$21.1M-$25.7M-$11.8M
Cash$11.5M$7.9M$5.5M$1.3M
SEC XBRL, fiscal years, as known on 2026-10-28

CALC Stock Sonar score 4/7 axes

Find similar shapesCompare

CALC ranks highest on risk and compliance (72nd percentile) and insider conviction (68th), and lowest on profitability (18th), among Pharma & Biotech peers.

Profitability
18
Inputs
  • Return on equity-365.7% · 11 pct, sector of 545
  • Return on assets-110.1% · 22 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-124.2% · 20 pct, sector of 576
Insider conviction
68
Inputs
  • Net Form 4 buying (codes P and S), 180d$199K · 80 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
27
Inputs
  • Funds adding, latest quarter15 · 27 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
72
Inputs
  • Short interest, % of float+2.3% · 72 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CALC filings, in plain words

Are CalciMedica insiders buying or selling CALC?

In the 180 days to 2026-10-28, CalciMedica insiders were net buyers, a net $199.2K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, CalciMedica insiders were net buyers of CALC, a net $199.2K across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $199.2K, came from a holder of 10% or more rather than an officer or director. 2 activist Schedule 13D filings in the last 180 days declared an intent to influence the company, the largest for 17.1% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies